618 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 2,428 published Semaglutide COA source records from third-party laboratories, covering 609 publicly attributable vendor identities. Across 2,222 records with positive numeric purity, the arithmetic mean is 99.66%. 12 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 3 positive purity results are below 90%; 90 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-20, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $5.50 | $5.50–$5.50 | $1.10 | 1 source · 1 offer |
| 10 mg | $8.00 | $8.00–$8.00 | $0.80 | 1 source · 1 offer |
| 15 mg | $9.50 | $9.00–$10.00 | $0.63 | 2 sources · 2 offers |
| 20 mg | $11.83 | $10.50–$13.00 | $0.59 | 3 sources · 3 offers |
| 30 mg | $16.00 | $14.00–$18.00 | $0.53 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-20T00:36:31.622173+00:00. Calculation time is not a laboratory observation date.
Within that total, 482 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 45 | 99.8% | 0 of 40 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #2 | 34 | 99.48% | 0 of 30 (0.0%) 0 0% / not detected · 0 wrong compound · 4 unclassified | Reveal with Pro → | |
| #3 | 29 | 99.43% | 0 of 29 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120870 (99.76%) · #120569 (99.95%) · #120845 (99.8%) · #120837 (99.85%) · #120830 (99.79%) · #120620 (99.57%)
This study aims to provide crucial **real-world validation** for **semaglutide** dose escalation from **0.5 mg** to **1.0 mg** weekly. For clinicians and individuals managing **Type 2 Diabetes**, robust real-world dat…
This real-world retrospective study reinforces the established efficacy and safety profile of weekly injectable semaglutide in a diverse patient population, specifically within a tertiary care setting in Pakistan. **F…
This re-analysis suggests that the initial declaration of failure for **semaglutide** in **Alzheimer's disease** may have been premature, highlighting the importance of evaluating longer-term data. **For individuals e…
This real-world comparison provides valuable insights for clinicians and patients weighing options for **obesity** management. **ESG offers a more rapid and pronounced initial weight loss effect compared to oral semag…
This research provides a crucial neural map of the DVC and pinpoints a specific, conserved pathway for cagrilintide's long-term metabolic benefits. **Understanding that cagrilintide's effects are mediated through `Prl…
**Clinicians should consider diabetes status and specific GLP-1 agent selection when prescribing for weight loss.** Non-diabetic individuals may expect substantially greater weight reduction, potentially influencing t…
This case underscores the importance of early diagnosis and a multi-pronged therapeutic approach for **Type B insulin resistance (TBIR)**, especially in atypical presentations. **Integrating GLP-1 receptor agonists li…
These findings suggest that **GLP-1 receptor agonists like semaglutide could serve as a novel adjunctive therapy to improve surgical outcomes in diabetic patients**, particularly those undergoing spinal procedures. Be…
**This study validates a locally developed semaglutide injection as an equally effective and safe alternative to the reference biologic for Indian T2DM patients.** This is a critical step towards enhancing access to `…
**Emergency physicians should be aware that semaglutide overdose can present with isolated neurologic symptoms like dysesthesia and asthenia, which may follow a benign, self-limited course.** This case expands the kno…
Semaglutide-induced weight loss is significantly reduced in obese patients who are diabetic, older, or of Hispanic ethnicity.
If this trial demonstrates that **semaglutide** significantly reduces both body weight and knee pain in individuals with obesity and OA, it could represent a major advancement in treatment. **This could establish sema…
A clinical trial aims to assess semaglutide's efficacy on body weight, insulin dose, glucose control, and safety in Type 1 Diabetes patients.
A Phase 3 trial will compare XW003 injection against semaglutide injection for efficacy and safety in Chinese adults with obesity.
NNC0194-0499 and semaglutide, alone or combined, are being investigated in a clinical trial for reducing liver damage in **NASH** patients.
**If successful, this trial could significantly expand semaglutide's indication to a broader population of obese individuals without diabetes**, offering a powerful new pharmacological tool for weight management. Curr…
Understanding semaglutide's direct impact on renal hemodynamics and specific physiological markers like `RAAS` activity and `GFR` is crucial for optimizing its use in **type 2 diabetes mellitus (T2DM)** patients with …
**Collecting real-world data on semaglutide's performance in Type 2 Diabetes is vital for clinicians and patients.** This observational study will provide valuable insights into how **semaglutide** functions outside t…
This prospective observational study is crucial for understanding how **Wegovy** performs in diverse, real-world settings, beyond the controlled environment of randomized clinical trials. **The findings will provide v…
**Semaglutide** users and clinicians should understand that while weight loss is beneficial, the accompanying lean mass reduction needs careful evaluation. This commentary highlights the ongoing debate: is the muscle …
Semaglutide's impact on inflammatory features in spinal implant-associated infection was explored across Type 1 and Type 2 diabetes models, addressing distinct disease pathologies.
This case report significantly expands the known adverse effect profile of semaglutide, particularly at supratherapeutic doses. **Emergency physicians should consider isolated neurologic symptoms like prolonged dysest…
If successful, this study could establish **Cagrilintide-semaglutide** (CagriSema) as a valuable add-on therapy for **type 2 diabetes** patients whose glycemic control remains inadequate despite basal insulin. **This …
While specific findings are pending, this phase 3 study design for CagriSema is highly significant for **type 2 diabetes** and **obesity management**. The combination of a **GLP-1 receptor agonist** (semaglutide) and …
The initiation of a Phase 3a trial for **CagriSema** marks a significant step towards a potentially more effective treatment for **type 2 diabetes** and **weight management**. This combination of a `GLP-1 receptor ago…
The rapid and substantial increase in GLP-1RA use among youth, particularly for weight management, underscores an urgent need for refined clinical protocols. **Clinicians must ensure specialist involvement in initiati…
This study provides crucial health economic evidence for the adoption of **semaglutide 2.4 mg** within the Spanish public health system. **For clinicians and policymakers, it validates semaglutide 2.4 mg as a cost-eff…
**Optimizing oral semaglutide formulations could significantly enhance patient adherence and expand access to this highly effective GLP-1 receptor agonist.** Improved bioavailability and reduced administration complex…
This study highlights that **demographic and clinical factors significantly influence semaglutide's real-world weight loss efficacy, necessitating personalized treatment expectations.** For clinicians and individuals …
This large cohort study provides crucial real-world evidence confirming an increased risk of gallstones and related complications with GLP-1 RA use in **T2DM** patients. **Clinicians prescribing GLP-1 RAs should couns…
This study is critical for understanding how **semaglutide** performs in specific East Asian populations, potentially informing more tailored treatment protocols for **obesity**. If positive, the findings could **expa…
If this trial demonstrates positive effects, **oral semaglutide could offer a more comprehensive management strategy for Type 2 Diabetes**, extending beyond glycemic control to address critical postprandial metabolic …
The initiation of a Phase 2 study for **PG-102** signifies a critical step in its development as a potential new treatment for **Type 2 Diabetes Mellitus**. If **PG-102** demonstrates favorable efficacy and safety, it…
If the ASCEND PLUS trial demonstrates positive results, it could significantly **expand the indication for semaglutide as a primary cardiovascular prevention strategy** in individuals with **type 2 diabetes** who are …
Semaglutide, a GLP-1RA, indicated potential to improve 90-day functional recovery in large vessel occlusion stroke patients after endovascular thrombectomy.
If this trial demonstrates that semaglutide effectively slows **Chronic Kidney Disease progression** in **Type 2 Diabetes** patients, it could significantly alter clinical practice. **Semaglutide could become a corner…
This research is crucial for understanding the broader therapeutic potential of **GLP-1 receptor agonists** beyond their established metabolic benefits. If positive mental health effects are confirmed, it could signif…
This case highlights the critical importance of **thorough baseline liver assessment** for individuals with underlying chronic liver diseases, such as **chronic viral hepatitis**, before initiating **semaglutide** or …
This advanced human six-tissue MPS provides an unprecedented platform for dissecting complex **inter-organ communication** in metabolic health and disease. For peptide users and biohackers, understanding how drugs lik…
This research introduces a promising strategy for developing next-generation GLP-1RAs that are significantly shorter than current market leaders, potentially offering advantages in synthesis, stability, and formulatio…
**Clinicians should consider implementing extended GLP-1 RA withholding, a 24-hour clear liquid diet, and pre-procedural gastric POCUS for patients undergoing elective procedures.** This evidence suggests a shift in p…
This advanced **six-tissue microphysiological system** represents a significant step forward in preclinical drug development for **metabolic diseases**. It offers a human-relevant platform to screen anti-diabetic comp…
Research explores how genetic and non-genetic factors vary across populations to influence sleep characteristics and broader health outcomes.
Understanding patient preferences for **obesity** pharmacotherapy is paramount for enhancing treatment adherence and achieving better long-term health outcomes. **Clinicians can leverage these insights to engage in mo…
This computational identification of <b>vorinostat</b> and other LSEC-protective compounds offers a significant step forward for <b>liver fibrosis</b> research. For clinicians and researchers, it provides novel, targe…
This case underscores the critical importance of considering **syphilis** in the differential diagnosis of atypical rectal masses, even when malignancy is strongly suspected. Misdiagnosis can lead to unnecessary invas…
This regulatory post-marketing surveillance study is crucial for understanding **Ozempic's (Semaglutide)** performance in a real-world setting, especially within the Korean **Type 2 Diabetes Mellitus** population. Whi…
SEMAFOLLOW is a real-world study evaluating **semaglutide 2.4 mg** effectiveness, weight change, and well-being in patients with Grade 3 and complicated obesity.
Understanding the interaction between **omeprazole** and **oral semaglutide** is crucial for optimizing treatment protocols for **type 2 diabetes** and **obesity**. If omeprazole significantly alters semaglutide absor…
Open-label clinical trial to evaluate oral **Semaglutide** for significant fibrosis due to **NAFLD** in obese or **T2DM** patients.
Free, no account — handy when you're working with Semaglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account